Analysts Set Q32 Bio Inc. (NASDAQ:QTTB) Target Price at $12.17

Shares of Q32 Bio Inc. (NASDAQ:QTTB) have been given an average rating of “Hold” by the eight analysts that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $12.1667.

Separately, Wall Street Zen downgraded Q32 Bio from a “hold” rating to a “sell” rating in a research report on Friday, July 18th.

Institutional Investors Weigh In On Q32 Bio

Several institutional investors and hedge funds have recently bought and sold shares of QTTB. Marshall Wace LLP bought a new stake in Q32 Bio during the second quarter worth about $25,000. Public Employees Retirement System of Ohio bought a new stake in Q32 Bio during the fourth quarter worth about $26,000. Raymond James Financial Inc. acquired a new position in Q32 Bio during the fourth quarter valued at approximately $37,000. Cubist Systematic Strategies LLC acquired a new position in Q32 Bio during the fourth quarter valued at approximately $42,000. Finally, Acadian Asset Management LLC acquired a new position in Q32 Bio during the first quarter valued at approximately $50,000. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Stock Performance

NASDAQ:QTTB opened at $1.81 on Friday. The stock has a market cap of $22.08 million and a P/E ratio of -0.42. The stock has a 50 day simple moving average of $1.88 and a 200 day simple moving average of $1.97. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 1.68. Q32 Bio has a 1-year low of $1.35 and a 1-year high of $53.79.

Q32 Bio (NASDAQ:QTTB) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.36. Research analysts anticipate that Q32 Bio will post -12.32 earnings per share for the current year.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.